MGNX Stock Overview
A biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
MacroGenics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.77 |
| 52 Week High | US$21.88 |
| 52 Week Low | US$2.75 |
| Beta | 2.01 |
| 1 Month Change | -18.77% |
| 3 Month Change | -36.32% |
| 1 Year Change | -84.86% |
| 3 Year Change | -75.89% |
| 5 Year Change | -72.95% |
| Change since IPO | -88.92% |
Recent News & Updates
Recent updates
MacroGenics: A Productive Biotech With Growing Potential - Still Not A Buy
Dec 05Party Time: Brokers Just Made Major Increases To Their MacroGenics, Inc. (NASDAQ:MGNX) Earnings Forecasts
Aug 01
MacroGenics, Inc.'s (NASDAQ:MGNX) Share Price Boosted 29% But Its Business Prospects Need A Lift Too
Jul 30We're A Little Worried About MacroGenics' (NASDAQ:MGNX) Cash Burn Rate
Jul 12MacroGenics, Inc.'s (NASDAQ:MGNX) 81% Dip In Price Shows Sentiment Is Matching Revenues
May 13MacroGenics: Strong Likelihood Bad News Has Caused Overreaction (Rating Upgrade)
May 13MacroGenics: Positive Safety Update Leads To Two Major Inflection Points In 2024
Apr 05MacroGenics, Inc. (NASDAQ:MGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Feb 28MacroGenics: Trying To Build A Better Everything
Feb 15There's No Escaping MacroGenics, Inc.'s (NASDAQ:MGNX) Muted Revenues
Jan 09Benign Growth For MacroGenics, Inc. (NASDAQ:MGNX) Underpins Its Share Price
May 17Analyst Forecasts For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher
Mar 11Here's Why MacroGenics (NASDAQ:MGNX) Must Use Its Cash Wisely
Jan 25Analysts' Revenue Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher
Oct 25MacroGenics: No Near-Term Catalysts
Oct 11Israel Englander and his Millennium fund disclose 5.2% passive stake in MacroGenics
Sep 02MacroGenics Q2 2022 Earnings Preview
Aug 05Companies Like MacroGenics (NASDAQ:MGNX) Could Be Quite Risky
Jul 25MacroGenics halts mid-stage head and neck cancer study after fatalities
Jul 11The Consensus EPS Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Just Fell Dramatically
May 09We're Keeping An Eye On MacroGenics' (NASDAQ:MGNX) Cash Burn Rate
Apr 12Shareholder Returns
| MGNX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.0% | 1.3% | 0.2% |
| 1Y | -84.9% | 0.9% | 22.0% |
Return vs Industry: MGNX underperformed the US Biotechs industry which returned 2.9% over the past year.
Return vs Market: MGNX underperformed the US Market which returned 22.4% over the past year.
Price Volatility
| MGNX volatility | |
|---|---|
| MGNX Average Weekly Movement | 7.8% |
| Biotechs Industry Average Movement | 11.4% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 18.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MGNX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MGNX's weekly volatility has decreased from 16% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 339 | Scott Koenig | www.macrogenics.com |
MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company’s pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies.
MacroGenics, Inc. Fundamentals Summary
| MGNX fundamental statistics | |
|---|---|
| Market cap | US$187.04m |
| Earnings (TTM) | -US$97.62m |
| Revenue (TTM) | US$141.33m |
1.2x
P/S Ratio-1.8x
P/E RatioIs MGNX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MGNX income statement (TTM) | |
|---|---|
| Revenue | US$141.33m |
| Cost of Revenue | US$192.63m |
| Gross Profit | -US$51.30m |
| Other Expenses | US$46.32m |
| Earnings | -US$97.62m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.56 |
| Gross Margin | -36.30% |
| Net Profit Margin | -69.07% |
| Debt/Equity Ratio | 0% |
How did MGNX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/06 05:26 |
| End of Day Share Price | 2025/02/06 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MacroGenics, Inc. is covered by 25 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Etzer Darout | BMO Capital Markets Equity Research |
| Stephen V. Byrne | BofA Global Research |